Revelation Biosciences REVB 深 滬
等待開盤 01-28 09:30:00 美东时间
0.523
-0.027
-4.93%
華盛通- 最 高0.5501
- 今 開0.507
- 成交量 277.12万股
- 最 低 0.47
- 昨 收 0.5501
- 總市值 309.83万
- 52周最高 13.62
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 0.47
- 委 比 -17.36%
- 總股本 592.41万
- 歷史最高 569016.00
- 量 比 0.11
- 振 幅 14.56%
- 歷史最低 0.47
- 每 手 1
- 風險率 4.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Revelation Biosciences Announces 1-for-4 Reverse Stock Split
Revelation Biosciences Announces 1-for-4 Reverse Stock Split Revelation Biosciences Inc. announced a 1-for-4 reverse stock split of its common stock, effective January 28, 2026. The stock will begin trading on a post-split basis under the existing symbol "REVB" on that date. The reverse split aims t
01-26 22:55
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise Revelation Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, allowing holders to purchase up to 13,065,000 shares of common stock at a reduced exercise price of $0.86 per share. In conne
01-26 15:33
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
01-23 15:02
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
Revelation Biosciences Reaches Agreement With FDA On Approval Pathway For Gemini To Treat Acute Kidney Injury
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached agreement with the
01-21 21:33
Revelation Biosciences Starts GMP Production Of GEMINI, Placebo
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and
01-07 22:04
Revelation Biosciences Extends Stock Warrants Expiration
Revelation Biosciences ( ($REVB) ) has provided an announcement. On December 3,...
2025-12-04 06:28
Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini, Its Acute Kidney Injury Treatment Candidate
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the
2025-11-20 22:05
Revelation Biosciences Reschedules Stockholder Meeting
Revelation Biosciences ( ($REVB) ) has shared an update. On October 29, 2025, R...
2025-10-30 04:59
Revelation Biosciences Adjourns Special Stockholders Meeting
Revelation Biosciences ( ($REVB) ) has provided an announcement. On October 15,...
2025-10-16 05:25
